New Biomarkers in the Prediction of Chemotherapy-induced Cardiotoxicity.
NCT ID: NCT05992337
Last Updated: 2023-08-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2021-09-01
2025-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Early Detection of Broken Hearts in Cancer Patients
NCT02086695
Optimising Screening for the Cardiotoxic Effects of Cancer Therapy
NCT06817044
PROactive Evaluation of Function to Avoid CardioToxicity
NCT03862131
Cardiotoxicity of Cancer Therapy (CCT)
NCT01173341
Early Detection of Cardiotoxicity From Systemic and Radiation Therapy in Breast Cancer Patients
NCT04790266
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Women with breast cancer treated with chemotherapeutics without signs of cardiotoxicity
Blood sampling
Blood sample collection for mRNA determination
Echocardiography
Echocardiography for detection of ventricular dysfunction
24-hours monitoring of ECG
Diagnostic test for detection of arrhythmias as a consequence of cardiotoxicity
Women with breast cancer treated with chemotherapeutics with signs of cardiotoxicity
Blood sampling
Blood sample collection for mRNA determination
Echocardiography
Echocardiography for detection of ventricular dysfunction
Cardio MRI
MRI for early detection of myocardial impairment caused by chemotherapy
24-hours monitoring of ECG
Diagnostic test for detection of arrhythmias as a consequence of cardiotoxicity
24 hours monitoring of BP
Diagnostic test for detection of hypertension as a consequence of cardiotoxicity
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood sampling
Blood sample collection for mRNA determination
Echocardiography
Echocardiography for detection of ventricular dysfunction
Cardio MRI
MRI for early detection of myocardial impairment caused by chemotherapy
24-hours monitoring of ECG
Diagnostic test for detection of arrhythmias as a consequence of cardiotoxicity
24 hours monitoring of BP
Diagnostic test for detection of hypertension as a consequence of cardiotoxicity
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Chemotherapy with a known cardiotoxic side effect
Exclusion Criteria
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
BioVendor LM
UNKNOWN
Oncology Center Medicon
UNKNOWN
Cardiology Prague
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cardiology Prague Ltd
Prague, , Czechia
Oncology Center Medicon
Prague, , Czechia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Version_Protocol_3_5_2021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.